Aclaris Therapeutics Inc (NASDAQ: ACRS) kicked off on Monday, down -3.77% from the previous trading day, before settling in for the closing price of $1.59. Over the past 52 weeks, ACRS has traded in a range of $0.95-$5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 72.53% over the last five years. While this was happening, its average annual earnings per share was recorded 64.89%. With a float of $91.37 million, this company’s outstanding shares have now reached $107.85 million.
The firm has a total of 64 workers. Let’s measure their productivity. In terms of profitability, gross margin is 17.43%, operating margin of -728.22%, and the pretax margin is -705.44%.
Aclaris Therapeutics Inc (ACRS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Aclaris Therapeutics Inc is 15.34%, while institutional ownership is 68.58%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares. Before that another transaction happened on Aug 05 ’24, when Company’s 10% Owner bought 206,025 for $1.24, making the entire transaction worth $256,357. This insider now owns 14,250,000 shares in total.
Aclaris Therapeutics Inc (ACRS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 64.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.51% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Take a look at Aclaris Therapeutics Inc’s (ACRS) current performance indicators. Last quarter, stock had a quick ratio of 3.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Analysing the last 5-days average volume posted by the [Aclaris Therapeutics Inc, ACRS], we can find that recorded value of 0.66 million was lower than the volume posted last year of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 30.03%. Additionally, its Average True Range was 0.12.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 1.75%, which indicates a significant decrease from 20.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.38% in the past 14 days, which was lower than the 117.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0588, while its 200-day Moving Average is $1.8984. Now, the first resistance to watch is $1.5783. This is followed by the second major resistance level at $1.6267. The third major resistance level sits at $1.6833. If the price goes on to break the first support level at $1.4733, it is likely to go to the next support level at $1.4167. Should the price break the second support level, the third support level stands at $1.3683.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
The company with the Market Capitalisation of 165.12 million has total of 107,919K Shares Outstanding. Its annual sales at the moment are 18,720 K in contrast with the sum of -132,070 K annual income. Company’s last quarter sales were recorded 9,210 K and last quarter income was -96,550 K.
